Coadministration of Anastrozole Sustains Therapeutic Testosterone Levels in Hypogonadal Men Undergoing Testosterone Pellet Insertion

Abstract

Introduction Current U.S. Food and Drug Administration–approved therapies for hypogonadism involve testosterone (T) replacement. Testosterone pellets (TP) require a minor office procedure every 3 to 4 months. The need for repeated insertions increases the likelihood of a complication. Anastrozole (AZ) is an aromatase inhibitor that has been used off-label for the treatment of male hypogonadism. AZ increases T levels by lowering serum estradiol (E2) levels and increasing gonadotropin (GTP) levels. Aim We hypothesized that the concomitant use of AZ with TP insertions would sustain therapeutic T levels and increase the interval between TP insertions. Methods Men treated with TP for hypogonadism at an academic center were offered AZ (1 mg/day) at the time of TP reinsertion as a way of potentially decreasing the frequency of TP insertions. Total T (TT), free T (FT), sex hormone binding globulin, E2, luteinizing hormone (LH), and follicle-stimulating hormone FSH levels were obtained prior to T replacement and at 6 and 15 weeks from TP insertion. Men were re-implanted at 16 weeks if their TT levels were less than 350 ng/dL and their symptoms recurred. We retrospectively reviewed our records of men who underwent TP, TP, and AZ from 2011 to 2012. Demographics, TT, FT, LH, FSH, and E2 levels were recorded. Data were analyzed with anova and a Tukey's test. Main Outcome Measure TT level at 6, 15, or >15 weeks from TP insertion. Results Thirty-eight men with 65 insertions were analyzed. The TP AZ group had significantly higher TT and FT levels than the TP group at >120 days (P < 0.05). The TP group had significantly higher E2 levels at all time points (P < 0.01). GTP levels remained stable in the TP AZ group. Average time to reinsertion in TP AZ was 198 days vs. 128 days in the TP group. Conclusion Men on TP AZ maintain therapeutic T levels longer than men on TP alone and have significantly less GTP suppression.

Androgen receptors beyond prostate cancer: an old marker as a new target

“…The latter may have special clinical relevance [ 54 ], especially since aromatase inhibitors, used to suppress estrogen levels in patients with ER+ breast tumors, can raise testosterone levels. As an example, anastrozole increases testosterone levels by decreasing serum estradiol levels [ 55 ]. Finally, PIK3CA/AKT/mTOR signaling is ubiquitously deregulated in cancer, and it is apparent that there is significant crosstalk between this pathway and that related to androgens (Figure 3 ).…”

The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy

“… 5 While AZ is commonly used as an adjunctive therapy to increase T levels in men whom spermatogenic preservation is important and therefore avoidance of exogenous testosterone is crucial, in our series AIs did not impact testosterone levels. However, other studies suggest coadministration of an AI with exogenous TTH increases serum T. 10 All of these received T pellets, suggesting a differential response based on TTH type.…”

A Review of Testosterone Pellets in the Treatment of Hypogonadism

“…Men on Testopel® and anastrozole did not demonstrate the secondary increase in their estradiol levels or suppression of their LH and FSH levels. The addition of a generic aromatase inhibitor significantly decreased the number of annual Testopel® insertions [ 18 •].…”